Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 64.07% is 348% above its 5-year average of 14.29%, near the high end of its 5-year range (10.51%–64.07%).
As of the fiscal period ended Tuesday, June 30, 2026. 65.47% above its 12-month average of 38.72%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 64.07%.
DEBT TO ASSETS RATIO
64.07%
DEBT TO ASSETS RATIO AVG TTM
38.72%
DEBT TO ASSETS RATIO AVG 3Y
15.79%
DEBT TO ASSETS RATIO AVG 5Y
14.29%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+65.47%
CURRENT VS 3Y AVG
+305.68%
CURRENT VS 5Y AVG
+348.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 866 covered companies
CURRENT VS SECTOR MEDIAN
+71091.77%
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.39B
Debt to Assets Ratio
64.07%
TTM Avg
38.72%
3Y Avg
15.79%
5Y Avg
14.29%
Market Cap
$4.42B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.44B
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.27B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.66B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.67B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.68B
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.69B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.39B | 64.07% | 38.72% | 15.79% | 14.29% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 0.41% | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.44B | 0.08% | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.27B | 0.01% | N/A | N/A | N/A |
| LivaNova PLC (LIVN)vs › | $4.14B | 0.13% | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 0.38% | N/A | N/A | N/A |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.67B | 0.03% | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 0.09% | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.69B | 0.00% | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.72B | 0.20% | N/A | N/A | N/A |
Debt/Assets
64.1%
Debt/Equity
2.87
Current Ratio
4.79
Interest Coverage
-4.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 64.07% |
| 2026-03-31 | 41.15% |
| 2025-12-31 | 54.72% |
| 2025-09-30 | 16.67% |
| 2025-06-30 | 16.99% |
| 2025-03-31 | 17.01% |
| 2024-12-31 | 16.57% |
| 2024-09-30 | 16.44% |
| 2024-06-30 | 16.10% |
| 2024-03-31 | 15.56% |
| 2023-12-31 | 14.94% |
| 2023-09-30 | 14.12% |
| 2023-06-30 | 13.54% |
| 2023-03-31 | 13.37% |
| 2022-12-31 | 12.61% |
| 2022-09-30 | 12.33% |
| 2022-06-30 | 13.80% |
| 2022-03-31 | 13.23% |
| 2021-12-31 | 12.10% |
| 2021-09-30 | 11.40% |
| 2021-06-30 | 10.51% |
| 2021-03-31 | 9.29% |
| 2020-12-31 | 9.66% |
| 2020-09-30 | 4.23% |
| 2020-06-30 | 5.35% |
| 2020-03-31 | 4.35% |
| 2019-12-31 | 4.01% |
| 2019-09-30 | 2.56% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
